Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Herbalife Nutrition Ltd (HLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Herbalife Nutrition Ltd — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 9.4× Herbalife Nutrition Ltd's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Herbalife Nutrition Ltd for 43 Days on average.
| HALO | HLF | |
|---|---|---|
Market Cap | $12.58B | $1.34B |
Volume | 2,179,278 | 1,589,457 |
Sector | Health | Consumer Staples |
52-Week High | $115.22 | $19.96 |
52-Week Low | $61.63 | $7.75 |
Typical Hold Time | 1 Days | 43 Days |
Enterprise Value | $14.49B | $3.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Herbalife (HLF) trades at $13.03, up 3.0% with a bullish technical signal. The stock shows attractive valuation metrics with P/E of 8.22 and P/S of 0.26, while maintaining strong gross margins of 77.7%. Recent Q1 2026 earnings beat expectations, though Q2 2026 missed. The company announced a $250 million share repurchase program and CEO transition, with management reaffirming 2026 guidance. Cash flow trends show improvement with projected positive net cash flow of $50 million for 2026.
HLF presents a value opportunity with discounted valuation and improving debt profile, though execution risks remain. Analyst consensus targets $19.00 (53.8% upside) with 14 buy ratings. Key risks include mixed earnings performance, high debt levels despite recent reduction, and leadership transition. The stock offers potential for re-rating if management delivers on margin expansion and growth targets outlined in recent investor presentations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →
